Daré Bioscience (NASDAQ:DARE) Stock Passes Above 50-Day Moving Average – What’s Next?

Daré Bioscience, Inc. (NASDAQ:DARE) passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $3.19 and traded as high as $3.23. Daré Bioscience shares last traded at $3.13, with a volume of 49,857 shares traded.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Price Performance

The firm’s 50-day simple moving average is $3.19 and its 200 day simple moving average is $3.38. The firm has a market capitalization of $27.23 million, a price-to-earnings ratio of -5.30 and a beta of 1.32.

Institutional Trading of Daré Bioscience

Several large investors have recently bought and sold shares of DARE. Jane Street Group LLC bought a new position in shares of Daré Bioscience in the fourth quarter worth about $52,000. Renaissance Technologies LLC grew its holdings in shares of Daré Bioscience by 6.7% during the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 4,300 shares during the last quarter. Geode Capital Management LLC increased its position in Daré Bioscience by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock worth $289,000 after purchasing an additional 3,593 shares in the last quarter. Finally, AMH Equity Ltd lifted its stake in Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 50,000 shares during the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.